Tecan’s Infinite® M1000 and Infinite F500 multimode readers are granted LanthaScreen™ Certified Plus status by Invitrogen Corporation

Tecan, a global leader in laboratory automation and detection, has been granted LanthaScreen™ Certified Plus status for selected Infinite^® multimode readers, by Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics. The certification is only given to microplate readers that meet high-level criteria for instrument set-up and performance with the LanthaScreen™ TR-FRET assay technology, and reflects the outstanding sensitivity and speed of the Infinite M1000 and Infinite F500 multimode microplate readers.

The Infinite M1000, the first monochromator-based instrument to receive LanthaScreen™ Certified Plus status, is Tecan’s new, high-end, premium quad4 monochromators™-based multimode instrument, providing outstanding flexibility, sensitivity and speed for demanding applications in drug discovery, life sciences and research.

The Infinite F500, Tecan’s high-end, filter-based multimode instrument, offers significantly improved performance for TR-FRET based measurements. The optional integration of reagent injectors (two injectors with selectable volumes), the optional 1,536-well reading capability, as well as ultra-lightweight programmable filter slides and automated z-focusing in all top reading modes, make this a powerful and versatile drug discovery tool in assay development and screening.

As part of a recent collaborative agreement, several Invitrogen drug discovery products have been validated by Invitrogen on the Infinite M1000 and Infinite F500 microplate readers, including GeneBLAzer^®, LanthaScreen™, Adapta™ Universal Kinase Assay, Z’-LYTE^®, Omnia^® and PolarScreen™.

To find out more on Tecan’s Infinite multimode readers